+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 366Days - 46Years
All Genders
ID06124157

International Study of Chemotherapy Combined With Dasatinib or Imatinib and Blinatumomab for Young Patients With Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia

Led by National Cancer Institute (NCI) · Updated on 2026-10-27

222

Participants Needed

161

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy to treat children, adolescents, and young adults with Philadelphia chromosome positive Ph or ABL-class Philadelphia chromosome-like Ph-like B-cell acute lymphoblastic leukemia B-ALL. This phase 2 trial aims to estimate event-free survival, overall survival, and safety profiles, including infections and neurotoxicity, over three years in these patients. The study also explores minimal residual disease negativity, immune function, and drug levels in the plasma and cerebrospinal fluid to better understand treatment response and outcomes. Participants receive a complex treatment plan based on their leukemia subtype. Those with Ph B-ALL receive a modified chemotherapy backbone combined with dasatinib and three cycles of blinatumomab, while patients with ABL-class Ph-like B-ALL receive similar chemotherapy with imatinib or dasatinib depending on gene fusion type. Treatment includes multiple phases such as induction, blinatumomab blocks, interim maintenance, delayed intensification, and maintenance cycles over about two years. Additional therapies like radiation, intrathecal methotrexate, and various chemotherapy drugs are also given as part of the regimen. Throughout the study, participants undergo regular evaluations including echocardiography or multigated acquisition scans during screening, as well as blood and cerebrospinal fluid collection and bone marrow biopsies at various points. Researchers closely monitor disease status, adverse events, and minimal residual disease using advanced tests. The primary outcomes measure event-free survival and adverse events up to three years, with secondary outcomes including overall survival and relapse rates. Participants remain under observation for safety and treatment response during the entire course of therapy.

CONDITIONS

Brief Title

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here